Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$15-$20 might be the offer but even after interim data release it would be laughable.
If so how many people who vowed to sell last year at $5 will actually do it?
You want to do your own due diligence and not rely on suggestions from a messageboard.
OOI is still a douche who writes his articles for the pennies they bring in. His Social Security check must not cover his expenses.
Is "no news" a technical indicator? If so I can't seem to find it anywhere on the chart.
Classical Technical Analysis Indistinguishable From Astrology
https://medium.com/@mikeharrisNY/classical-technical-analysis-indistinguishable-from-astrology-1bb8b0c182cf
It's common knowledge that the FDA does not announce that.
Drugs with a good safety profile, good efficacy and an unmet need in lethal diseases can be approved on phase 2. Leronlimab meets that criteria for COVID-19.
You haven't put forward a hypothesis, only an unsupported assertation.
Down to where?
That dead cat was filled with rocket fuel and launched.
I've heard that Nader sold because of bad news. Now insiders aren't selling because of bad news.
We'll need the share price increase from Cytodyn just to cover inflation.
5) You expect the share price to rise high enough that you will be selling some or all somewhat over 12 months from now and want the long term capital gains tax.
No it's not. :)
Busy looking for inconsequentials that can be twisted and any technical analysis that can support their preconceived biases.
It does seem rather quiet here this morning.
It is what it is unless it ain't what it ain't.
Strange that most technical indicator sites list Cytodyn as "BUY" or "BULLISH".
Both cancer and NASH will be done well before 5 years. At the outside I think we'll trip past $100 within 2 years.
I figure Gilead and Cytodyn's stock prices will cross paths around $45 as Gilead goes further down and Cytodyn goes further up.
Placebo is cheaper and reduces the viral load the same.
I can remember last year when I was excoriated for suggesting $100 a share for HIV, cancer and NASH.
Let's just look at NASH in the U.S. It is estimated that 10 million U.S. adults have NASH, not the less serious NAFLD. In a previous analysis I used 20% market penetration across all indications. Let's go even more conservative and say 10%. That would mean 1 million patients.
Assume $30,000 cost after discounts etc. - $1,000 overhead for sales = $29,000 / 2 (50% after net) = $14,500 - 6.5% royalty @ $30k ($1950) = $12,550 - $500 internal overhead = $12,050 earnings
1,000,000 patients x $12,050 = $12.05 billion in earnings x 12 EPS = $144.6 billion market cap / 730 million shares = $198 per share
Even if there's only 2% market penetration that's $39 for just NASH.
Maybe ATHX shareholders that are abandoning that sinking ship are coming over here. ATHX should release some PRs.